Skip to main content
In stock|Targeted Therapy (Antibody)

Moxetumomab Pasudotox

Oncology TypeHematologic (Leukemia)
Drug Class / MechanismAnti-CD22 Pseudomonas Exotoxin Immunotoxin
No Image
Description

Moxetumomab Pasudotox is classified as an Anti-CD22 Pseudomonas Exotoxin Immunotoxin, sourced for use within our Targeted Therapy (Antibody) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy (Antibody)
Oncology TypeHematologic (Leukemia)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3